Y-mAbs Therapeutics (YMAB) expects to raise $80 million in an initial public offering on Friday, September 21st, IPO Scoop reports. The company will be issuing 5,300,000 shares at $14.00-$16.00 per share.

Y-mAbs Therapeutics has a market cap of $489.4 million.

BofA Merrill Lynch, Cowen and Canaccord Genuity served as the underwriters for the IPO and BTIG was co-manager.

Y-mAbs Therapeutics provided the following description of their company for its IPO: ”  We are a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. We have a broad and advanced product pipeline, including two pivotal-stage product candidates—naxitamab and omburtamab—which target tumors that express GD2 and B7-H3, respectively. We are developing naxitamab for the treatment of pediatric patients with relapsed or refractory, or R/R, high-risk neuroblastoma, or NB, and radiolabeled omburtamab for the treatment of pediatric patients with central nervous system, or CNS, leptomeningeal metastases, or LM, from NB. NB is a rare and almost exclusively pediatric cancer that develops in the sympathetic nervous system and CNS/LM is a rare and usually fatal complication of NB in which the disease spreads to the membranes, or meninges, surrounding the brain and spinal cord in the CNS. “.

Y-mAbs Therapeutics was founded in 2015 and has 29 employees. The company is located at 230 Park Avenue, 33rd Floor, New York, NY 10169, US and can be reached via phone at (212) 847-9841 or on the web at http://www.ymabs.com.

Receive News & Ratings for Y-mAbs Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Y-mAbs Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.